Low Dose Intravenous Iron Sucrose Maintenance Therapy in Hemodialysis Patients with Adequate Iron Storage / 대한신장학회잡지

ABSTRACT

BACKGOUND In addition to recombinant human erythropoietin (rHuEPO) adequate iron replacement is essential to treatment of anemia in hemodialysis (HD) patients, and intravenous iron therapy has been recommended recently. But, low dose (100-200 mg/ month) intravenous iron sucrose regimen as a "maintenance therapy" in HD patients with adequate iron storage has not been established well. METHODS: We included the 40 of HD patients with serum ferritin of 200-500 ng/mL receiving rHuEPO therapy. During 4 months of study period, 100-200 mg/month of iron sucrose was administrated. rHuEPO doses were titrated to maintain target hematocrit (Hct) of 30%. To evaluate efficacy of iron sucrose, we compared serum ferritin, TSAT and rHuEPO requirements before and after iron sucrose therapy. RESULTS: Thirty-nine patients [mean age 61+/-13 yrs, MF=2019] completed this study. After low dose intravenous iron sucrose maintenance therapy, serum ferritin and TSAT significantly increased (370+/-84 vs. 518+/-155 ng/mL, p800 ng/mL was observed during the study. CONCLUSION: Low dose intravenous iron sucrose maintenance therapy is effective and safe in the HD patient receiving rHuEPO therapy with adequate iron storage.